Affiliation:
1. Department of Chemical Engineering, Pennsylvania State University, University Park 16802, PA, USA
Abstract
The performance of virus filters is often determined by the extent of protein fouling, which can affect both filtrate flux and virus retention. However, the mechanisms governing changes in virus retention in the presence of proteins are still not well understood. The objective of this work was to examine the effect of proteins on virus retention by both asymmetric (Viresolve® NFP and Viresolve® Pro) and relatively homogeneous (Ultipor® DV20 and PegasusTM SV4) virus filtration membranes. Experiments were performed with bacteriophage ϕX174 as a model parvovirus and human serum immunoglobulin G (hIgG) as a model protein. The virus retention in 1 g/L hIgG solutions was consistently less than that in a protein-free buffer solution by between 1 to 3 logs for the different virus filters. The virus retention profiles for the two homogeneous membranes were very similar, with the virus retention being highly correlated with the extent of flux decline. Membranes prefouled with hIgG and then challenged with phages also showed much lower virus retention, demonstrating the importance of membrane fouling; the one exception was the Viresolve® Pro membrane, which showed a similar virus retention for the prefouled and pristine membranes. Experiments in which the protein was filtered after the virus challenge demonstrated that hIgG can displace previously captured viruses from within a filter. The magnitude of these effects significantly varied for the different virus filters, likely due to differences in membrane morphology, pore size distribution, and chemistry, providing important insights into the development/application of virus filtration in bioprocessing.
Reference24 articles.
1. Biopharmaceutical Benchmarks 2014;Walsh;Nat. Biotechnol.,2014
2. Virus contaminations of cell cultures—A biotechnological view;Merten;Cytotechnology,2002
3. (1998). International Conference on Harmonisation, Guidance on Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin, Availability—FDA. Federal Register Notices., 63, 51074–51084. Available online: https://www.federalregister.gov/documents/1998/09/24/98-25569/international-conference-on-harmonisation-guidance-on-viral-safety-evaluation-of-biotechnology.
4. Viral Clearance for Biopharmaceutical Downstream Processes;Shukla;Pharm. Bioprocess.,2015
5. Viral Contamination in Biologic Manufacture and Implications for Emerging Therapies;Barone;Nat. Biotechnol.,2020